Paulo Louzada-Junior

Paulo Louzada-Junior

Auto-generated profile, based on publicly available information

Paulo Louzada-Junior

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FVFlavio Protasio Veras
Flavio Protasio Veras
MPMarjorie Pontelli
Marjorie Pontelli
CSCamila Meirelles Silva
Camila Meirelles Silva
JTJuliana E. Toller-Kawahisa
Juliana E. Toller-Kawahisa
MLMikhael Haruo Fernandes Lima
Mikhael Haruo Fernandes Lima
FCFernando Queiroz Cunha
Fernando Queiroz Cunha
Severe COVID-19 patients develop acute respiratory distress syndrome that may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that neutrophil extracellular traps (NETs) have been described as important mediators of tissue damage in inflammatory diseases, we investigated whether NETs would be involved in COVID-19 pathophysiology. A cohort of 32 hospitalized patients with a confirmed diagnosis of COVID-19 and healthy controls were enrolled. The concentration of NETs was augmented in plasma, tracheal aspirate, and lung autopsies tissues from COVID-19 patients, and their neutrophils released higher levels of NETs. Notably, we found that viable SARS-CoV-2 can directly induce the release of NETs by healthy neutrophils. Mechanistically, NETs triggered by SARS-CoV-2 depend on angiotensin-converting enzyme 2, serine protease, virus replication, and PAD-4. Finally, NETs released by SARS-CoV-2–activated neutrophils promote lung epithelial cell death in vitro. These results unravel a possible detrimental role of NETs in the pathophysiology of COVID-19. Therefore, the inhibition of NETs represents a potential therapeutic target for COVID-19.

24 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TRTamara S. Rodrigues
Tamara S. Rodrigues
KSKeyla Sá
Keyla Sá
AIAdriene Y. Ishimoto
Adriene Y. Ishimoto
ABAmanda Becerra
Amanda Becerra
SOSamuel Oliveira
Samuel Oliveira
DZDario S. Zamboni
Dario S. Zamboni
Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1β, and IL-18. Although participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease are unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and is active in COVID-19 patients. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of postmortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that inflammasomes participate in the pathophysiology of the disease, indicating that these platforms might be a marker of disease severity and a potential therapeutic target for COVID-19.

11 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
FCFernanda Crunfli
Fernanda Crunfli
VCVictor Carregari
Victor Carregari
FVFlavio P. Veras
Flavio P. Veras
LSLucas S. Silva
Lucas S. Silva
MNMateus Henrique Nogueira
Mateus Henrique Nogueira
DMDaniel Martins-de-Souza
Daniel Martins-de-Souza
Although increasing evidence confirms neuropsychiatric manifestations associated mainly with severe COVID-19 infection, long-term neuropsychiatric dysfunction (recently characterized as part of “long COVID-19” syndrome) has been frequently observed after mild infection. We show the spectrum of cerebral impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, ranging from long-term alterations in mildly infected individuals (orbitofrontal cortical atrophy, neurocognitive impairment, excessive fatigue and anxiety symptoms) to severe acute damage confirmed in brain tissue samples extracted from the orbitofrontal region (via endonasal transethmoidal access) from individuals who died of COVID-19. In an independent cohort of 26 individuals who died of COVID-19, we used histopathological signs of brain damage as a guide for possible SARS-CoV-2 brain infection and found that among the 5 individuals who exhibited those signs, all of them had genetic material of the virus in the brain. Brain tissue samples from these five patients also exhibited foci of SARS-CoV-2 infection and replication, particularly in astrocytes. Supporting the hypothesis of astrocyte infection, neural stem cell–derived human astrocytes in vitro are susceptible to SARS-CoV-2 infection through a noncanonical mechanism that involves spike–NRP1 interaction. SARS-CoV-2–infected astrocytes manifested changes in energy metabolism and in key proteins and metabolites used to fuel neurons, as well as in the biogenesis of neurotransmitters. Moreover, human astrocyte infection elicits a secretory phenotype that reduces neuronal viability. Our data support the model in which SARS-CoV-2 reaches the brain, infects astrocytes, and consequently, leads to neuronal death or dysfunction. These deregulated processes could contribute to the structural and functional alterations seen in the brains of COVID-19 patients.

1 September 2010 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WVWaldiceu Verri
Waldiceu Verri
FSFabrício O Souto
Fabrício O Souto
SVSilvio M Vieira
Silvio M Vieira
SASergio C L Almeida
Sergio C L Almeida
SFSandra Y Fukada
Sandra Y Fukada
FCFernando Q Cunha
Fernando Q Cunha
Objectives Interleukin 33 (IL-33) is a new member of the IL-1 family of cytokines which signals via its receptor, ST2 (IL-33R), and has an important role in Th2 and mast cell responses. This study shows that IL-33 orchestrates neutrophil migration in arthritis. Methods and results Methylated bovine serum albumin (mBSA) challenge in the knee joint of mBSA-immunised mice induced local neutrophil migration accompanied by increased IL-33R and IL-33 mRNA expression. Cell migration was inhibited by systemic and local treatments with soluble (s)IL-33R, an IL-33 decoy receptor, and was not evident in IL-33R-deficient mice. IL-33 injection also induced IL-33R-dependent neutrophil migration. Antigen- and IL-33-induced neutrophil migration in the joint was dependent on CXCL1, CCL3, tumour necrosis factor α (TNFα) and IL-1β synthesis. Synovial tissue, macrophages and activated neutrophils expressed IL-33R. IL-33 induces neutrophil migration by activating macrophages to produce chemokines and cytokines and by directly acting on neutrophils. Importantly, neutrophils from patients with rheumatoid arthritis successfully treated with anti-TNFα antibody (infliximab) expressed significantly lower levels of IL-33R than patients treated with methotrexate alone. Only neutrophils from patients treated with methotrexate alone or from normal donors stimulated with TNFα responded to IL-33 in chemotaxis. Conclusions These results suggest that suppression of IL-33R expression in neutrophils, preventing IL-33-induced neutrophil migration, may be an important mechanism of anti-TNFα therapy of inflammation.

1 July 1992 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
PLP. Louzada‐Junior
P. Louzada‐Junior
JDJ. J. Dias
J. J. Dias
WSW. F. Santos
W. F. Santos
JLJ. J. Lachat
J. J. Lachat
HBH. F. Bradford
H. F. Bradford
JCJ. Coutinho‐Netto
J. Coutinho‐Netto

9 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RPRaphael Sanches Peres
Raphael Sanches Peres
FLFoo Y. Liew
Foo Y. Liew
JTJhimmy Talbot
Jhimmy Talbot
VCVanessa Carregaro
Vanessa Carregaro
RORene D. Oliveira
Rene D. Oliveira
FCFernando Q. Cunha
Fernando Q. Cunha
Significance: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). However, about 40% of patients are resistant to MTX. Furthermore, MTX resistance is only apparent after a prolonged continuous MTX treatment (>3 mo), by which time the disease of the nonresponders would have aggravated. Thus, there is a considerable unmet need for a biomarker to select MTX-resistant patients and place them immediately on alternative therapy. We found here that the low density of CD39 on peripheral regulatory T cells in RA patients is a rapid, convenient, and reliable ( P < 0.01) biomarker for MTX resistance. Our findings also provide previously unrecognized information on aspects of immune regulation in RA and the mechanism of action of MTX.